The Effect of Adenovirus-Mediated Gene Expression of FHIT in Small Cell Lung Cancer Cells

REFERENCES

• Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385–1396.
   PubMed Web of Science ®Google Scholar
• Wali A. FHIT: doubts are clear now. Sci. World J 2010; 10:1142–1151.
   Google Scholar
• Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, Pierotti MA, Ohta M, Huebner K, Croce CM. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996;85:17–26.
   PubMed Web of Science ®Google Scholar
• Rohr UP, Rehfeld N, Geddert H, Pflugfelder L, Bruns I, Neukirch J, Rohrbeck A, Grote HJ, Steidl U, Fenk R, Opalka B, Gabbert HE, Kronenwett R, Haas R. Prognostic relevance of fragile histidine triad protein expression in patients with small cell lung cancer. Clin Cancer Res 2005;11:180–185.
   PubMed Web of Science ®Google Scholar
• Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999;59:3333–3339.
   PubMed Web of Science ®Google Scholar
• Xu RH, Zheng LY, He DL, Tong J, Zheng LP, Zheng WP, Meng J, Xia LP, Wang CJ, Yi JL. Effect of fragile histidine triad gene transduction on proliferation and apoptosis of human hepatocellular carcinoma cells. World J Gastroenterol 2008;14:3754–3758.
   PubMed Web of Science ®Google Scholar
• Zanesi N, Fidanza V, Fong LY, Mancini R, Druck T, Valtieri M, Rudiger T, McCue PA, Croce CM, Huebner K. The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci USA 2001;98:10250–10255.
   PubMedGoogle Scholar
• Dumon KR, Ishii H, Fong LY, Zanesi N, Fidanza V, Mancini R, Vecchione A, Baffa R, Trapasso F, During MJ, Huebner K, Croce CM. FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci USA 2001;98:3346–3351.
   PubMed Web of Science ®Google Scholar
• Christensen CL, Zandi R, Gjetting T, Cramer F, Poulsen HS. Specifically targeted gene therapy for small-cell lung cancer. Expert Rev Anticancer Ther 2009;9:437–452.
   PubMed Web of Science ®Google Scholar
• Sanchez-Cespedes M. Dissecting the genetic alterations involved in lung carcinogenesis. Lung Cancer 2003;40:111–121.
   PubMed Web of Science ®Google Scholar
• Nishizaki M, Sasaki J, Fang B, Atkinson EN, Minna JD, Roth JA, Ji L. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res 2004;64:5745–5752.
   PubMed Web of Science ®Google Scholar
• Cavazzoni A, Galetti M, Fumarola C, Alfieri RR, Roz L, Andriani F, Carbognani P, Rusca M, Sozzi G, Petronini PG. Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line. Cancer Lett 2007;246:69–81.
   PubMed Web of Science ®Google Scholar
• Zandi R, Selivanova G, Christensen CL, Gerds TA, Willumsen BM, Poulsen HS. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin Cancer Res 2011;17(9):2830–2841.
   PubMed Web of Science ®Google Scholar
• Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002;8:282–288.
   PubMed Web of Science ®Google Scholar
• Bykov VJ, Zache N, Stridh H, Westman J, Bergman J, Selivanova G, Wiman KG. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 2005;24:3484–3491.
   PubMed Web of Science ®Google Scholar
• Bykov VJ, Issaeva N, Selivanova G, Wiman KG. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 2002;23:2011–2018.
   PubMed Web of Science ®Google Scholar
• Shen J, Vakifahmetoglu H, Stridh H, Zhivotovsky B, Wiman KG. PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2. Oncogene 2008;27:6571–6580.
   PubMed Web of Science ®Google Scholar
• Wang T, Lee K, Rehman A, Daoud SS. PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax. Biochem Biophys Res Commun 2007;352:203–212.
   PubMed Web of Science ®Google Scholar
• Li Y, Mao Y, Brandt-Rauf PW, Williams AC, Fine RL. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway. Mol Cancer Ther 2005;4:901–909.
   PubMed Web of Science ®Google Scholar
• Lambert JM, Moshfegh A, Hainaut P, Wiman KG, Bykov VJ. Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene 2010;29:1329–1338.
   PubMed Web of Science ®Google Scholar
• Charlot JF, Nicolier M, Pretet JL, Mougin C. Modulation of p53 transcriptional activity by PRIMA-1 and Pifithrin-alpha on staurosporine-induced apoptosis of wild-type and mutated p53 epithelial cells. Apoptosis 2006;11:813–827.
   PubMed Web of Science ®Google Scholar
• Nahi H, Merup M, Lehmann S, Bengtzen S, Mollgard L, Selivanova G, Wiman KG, Paul C. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br J Haematol 2006;132:230–236.
   PubMed Web of Science ®Google Scholar
• Shi H, Lambert JM, Hautefeuille A, Bykov VJ, Wiman KG, Hainaut P, de Fromentel CC. In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249. Carcinogenesis 2008;29:1428–1434.
   PubMed Web of Science ®Google Scholar
• Liang Y, Besch-Williford C, Hyder SM. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. Int J Oncol 2009;35:1015–1023.
   PubMed Web of Science ®Google Scholar
• Pedersen N, Mortensen S, Sorensen SB, Pedersen MW, Rieneck K, Bovin LF, Poulsen HS. Transcriptional gene expression profiling of small cell lung cancer cells. Cancer Res 2003;63:1943–1953.
   PubMed Web of Science ®Google Scholar
• Chou TC, Talaly P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis–Menten kinetic systems. J Biol Chem 1977;252:6438–6442.
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis–Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981;115:207–216.
   PubMedGoogle Scholar
• Chou TC, Talalay P. Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents. In New Avenues in Developmental Cancer Chemotherapy, KR Harrap and TA Connors (eds.). New York: Academic Press, 1987, 37–64.
   Google Scholar
• Chou TC. Quantitation of synergism and antagonism of two or more drugs by computerized analysis. In Synergism and Antagonism in Chemotherapy, TC Chou and DC Rideout (eds.). New York: Academic Press, 1991, 223–244.
   Google Scholar
• Ishii H, Dumon KR, Vecchione A, Trapasso F, Mimori K, Alder H, Mori M, Sozzi G, Baffa R, Huebner K, Croce CM. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 2001;61:1578–1584.
   PubMed Web of Science ®Google Scholar
• Kelley K, Berberich SJ. FHIT gene expression is repressed by mitogenic signaling through the PI3K/AKT/FOXO pathway. Am J Cancer Res 2011;1:62–70.
   Web of Science ®Google Scholar
• Popovici C, Basset C, Bertucci F, Orsetti B, Adelaide J, Mozziconacci MJ, Conte N, Murati A, Ginestier C, Charafe-Jauffret E, Ethier SP, Lafage-Pochitaloff M, Theillet C, Birnbaum D, Chaffanet M. Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene. Genes Chromosomes Cancer 2002;35:204–218.
   PubMed Web of Science ®Google Scholar
• Jayachandran G, Sazaki J, Nishizaki M, Xu K, Girard L, Minna JD, Roth JA, Ji L. Fragile histidine triad-mediated tumor suppression of lung cancer by targeting multiple components of the Ras/Rho GTPase molecular switch. Cancer Res 2007;67:10379–10388.
   Google Scholar
• Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001;28:3–13.
   PubMed Web of Science ®Google Scholar
• Dumon KR, Ishii H, Vecchione A, Trapasso F, Baldassarre G, Chakrani F, Druck T, Rosato EF, Williams NN, Baffa R, During MJ, Huebner K, Croce CM. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res 2001;61:4827–4836.
   PubMed Web of Science ®Google Scholar
• Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, Sard L, Tagliabue E, Greco A, Fusetti L, Schwartz G, Pierotti MA, Croce CM, Huebner K. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997;94:13771–13776.
   PubMed Web of Science ®Google Scholar
• Wu R, Connolly DC, Dunn RL, Cho KR. Restored expression of fragile histidine triad protein and tumorigenicity of cervical carcinoma cells. J Natl Cancer Inst 2000;92:338–344.
   PubMed Web of Science ®Google Scholar
• Otterson GA, Xiao GH, Geradts J, Jin F, Chen WD, Niklinska W, Kaye FJ, Yeung RS. Protein expression and functional analysis of the FHIT gene in human tumor cells. J Natl Cancer Inst 1998;90:426–432.
   PubMed Web of Science ®Google Scholar
• Werner NS, Siprashvili Z, Fong LY, Marquitan G, Schroder JK, Bardenheuer W, Seeber S, Huebner K, Schutte J, Opalka B. Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression. Cancer Res 2000;60:2780–2785.
   PubMed Web of Science ®Google Scholar
• Deng WG, Nishizaki M, Fang B, Roth JA, Ji L. Induction of apoptosis by tumor suppressor FHIT via death receptor signaling pathway in human lung cancer cells. Biochem Biophys Res Commun 2007;355:993–999.
   PubMed Web of Science ®Google Scholar
• Roz L, Andriani F, Ferreira CG, Giaccone G, Sozzi G. The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression. Oncogene 2004;23:9102–9110.
   PubMed Web of Science ®Google Scholar